Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer - PubMed (original) (raw)

Multicenter Study

. 2016 Jul;128(1):127-137.

doi: 10.1097/AOG.0000000000001491.

Sigita S Cahoon, Kosuke Yoshihara, Masako Shida, Mamoru Kakuda, Sosuke Adachi, Aida Moeini, Hiroko Machida, Jocelyn Garcia-Sayre, Yutaka Ueda, Takayuki Enomoto, Mikio Mikami, Lynda D Roman, Anil K Sood

Affiliations

Multicenter Study

Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer

Koji Matsuo et al. Obstet Gynecol. 2016 Jul.

Abstract

Objective: To examine the survival outcomes in women with endometrial cancer who were taking low-dose aspirin (81-100 mg/d).

Methods: A multicenter retrospective study was conducted examining patients with stage I-IV endometrial cancer who underwent hysterectomy-based surgical staging between January 2000 and December 2013 (N=1,687). Patient demographics, medical comorbidities, medication types, tumor characteristics, and treatment patterns were correlated to survival outcomes. A Cox proportional hazard regression model was used to estimate adjusted hazard ratio for disease-free and disease-specific overall survival.

Results: One hundred fifty-eight patients (9.4%, 95% confidence interval [CI] 8.8-11.9) were taking low-dose aspirin. Median follow-up time for the study cohort was 31.5 months. One hundred twenty-seven patients (7.5%) died of endometrial cancer. Low-dose aspirin use was significantly correlated with concurrent obesity, hypertension, diabetes mellitus, and hypercholesterolemia (all P<.001). Low-dose aspirin users were more likely to take other antihypertensive, antiglycemic, and anticholesterol agents (all P<.05). Low-dose aspirin use was not associated with histologic subtype, tumor grade, nodal metastasis, or cancer stage (all P>.05). On multivariable analysis, low-dose aspirin use remained an independent prognostic factor associated with an improved 5-year disease-free survival rate (90.6% compared with 80.9%, adjusted hazard ratio 0.46, 95% CI 0.25-0.86, P=.014) and disease-specific overall survival rate (96.4% compared with 87.3%, adjusted hazard ratio 0.23, 95% CI 0.08-0.64, P=.005). The increased survival effect noted with low-dose aspirin use was greatest in patients whose age was younger than 60 years (5-year disease-free survival rates, 93.9% compared with 84.0%, P=.013), body mass index was 30 or greater (92.2% compared with 81.4%, P=.027), who had type I cancer (96.5% compared with 88.6%, P=.029), and who received postoperative whole pelvic radiotherapy (88.2% compared with 61.5%, P=.014). These four factors remained significant for disease-specific overall survival (all P<.05).

Conclusion: Our results suggest that low-dose aspirin use is associated with improved survival outcomes in women with endometrial cancer, especially in those who are young, obese, with low-grade disease, and who receive postoperative radiotherapy.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure

The authors did not report any potential conflicts of interest.

Figures

Fig. 1.

Fig. 1.

Survival curves of endometrial cancer based on low-dose aspirin (ASA) use. Log-rank test for P values. Survival curves were constructed for (A) disease-free survival, (B) disease-specific overall survival, (C) body mass index (BMI), and (D) postoperative whole pelvic radiotherapy (WPRT).

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30. -PubMed
    1. Sturm R, Hattori A. Morbid obesity rates continue to rise rapidly in the United States. Int J Obes (Lond) 2013;37:889–91. -PMC -PubMed
    1. Cauley JA, Gutai JP, Kuller LH, LeDonne D, Powell JG. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989;129:1120–31. -PubMed
    1. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancerrelated inflammation and treatment effectiveness. Lancet Oncol 2014;15:e493–503. -PubMed
    1. Modugno F, Ness RB, Chen C, Weiss NS. Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol Biomarkers Prev 2005;14:2840–7. -PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources